医药高增长轮动策略:年化收益率(5.6%)
本策略精选医药生物行业中,净利润和营收均高速增长、毛利率和净利率优秀、市盈率适中,且流通市值较小的优质股票。策略通过严格的财务指标筛选,并结合小市值偏好,力求捕捉医药行业中具备高成长潜力的投资标的,并进行短期轮动持有,以期获得超额收益。
本策略精选医药生物行业中,净利润和营收均高速增长、毛利率和净利率优秀、市盈率适中,且流通市值较小的优质股票。策略通过严格的财务指标筛选,并结合小市值偏好,力求捕捉医药行业中具备高成长潜力的投资标的,并进行短期轮动持有,以期获得超额收益。
查看AI策略代码
当日收盘价 | 当日市值 | 浮动收益/浮动收益率
|
|||||
---|---|---|---|---|---|---|---|
2025-08-01 | 甘李药业(603087.SH) | 48.368603968939 | 1830 | 62 | 60.99 | 111611.7 | 23097.15/26.094% |
2025-08-01 | 昊帆生物(301393.SZ) | 48.364578054629 | 1909 | 62 | 59.05 | 112726.45 | 20398.47/22.093% |
2025-08-01 | 大博医疗(002901.SZ) | 33.655879985364 | 2433 | 67 | 44.68 | 108706.44 | 26821.68/32.755% |
2025-08-01 | 兴齐眼药(300573.SZ) | 55.206555555556 | 1700 | 12 | 61.75 | 104975 | 11123.86/11.853% |
2025-08-01 | 宣泰医药(688247.SH) | 10.709931934519 | 8533 | 182 | 12.41 | 105894.53 | 14506.68/15.874% |
2025-08-01 | 特宝生物(688278.SH) | 61.435341940248 | 1239 | 322 | 90.73 | 112414.47 | 36296.08/47.684% |
2025-07-31 | 甘李药业(603087.SH) | 48.368603968939 | 1830 | 61 | 57.9 | 105957 | 17442.45/19.706% |
2025-07-31 | 昊帆生物(301393.SZ) | 48.364578054629 | 1909 | 61 | 61.69 | 117766.21 | 25438.23/27.552% |
2025-07-31 | 大博医疗(002901.SZ) | 33.655879985364 | 2433 | 66 | 44.26 | 107684.58 | 25799.82/31.507% |
2025-07-31 | 兴齐眼药(300573.SZ) | 55.206555555556 | 1700 | 11 | 64.53 | 109701 | 15849.86/16.888% |
2025-07-31 | 宣泰医药(688247.SH) | 卖 | -200 | 12.6 | -2520 | ¥7.52 | 378.01 |
2025-07-31 | 兴齐眼药(300573.SZ) | 卖 | -100 | 64.09 | -6409 | ¥11.41 | 888.34 |
2025-07-24 | 宣泰医药(688247.SH) | 卖 | -500 | 11.8 | -5900 | ¥10.9 | 545.03 |
2025-07-24 | 大博医疗(002901.SZ) | 卖 | -100 | 43.18 | -4318 | ¥9.32 | 952.41 |
2025-07-17 | 兴齐眼药(300573.SZ) | 买 | 1800 | 55.19 | 99342 | ¥29.8 | 0 |
2025-07-17 | 大博医疗(002901.SZ) | 卖 | -200 | 41.25 | -8250 | ¥13.25 | 1518.82 |
2025-07-10 | 宣泰医药(688247.SH) | 卖 | -400 | 10.67 | -4268 | ¥9.27 | -15.97 |
2025-06-27 | 宣泰医药(688247.SH) | 买 | 38 | 10.08 | -0.76 | ¥0 | 0 |
2025-06-26 | 昊帆生物(301393.SZ) | 买 | 100 | 51.18 | 5118 | ¥5 | 0 |
2025-06-19 | 大博医疗(002901.SZ) | 买 | 100 | 35.5 | 3550 | ¥5 | 0 |